SCOPUS 정보 검색 플랫폼

Volumn 79, Issue 10, 2009, Pages 672-673

Gastrointestinal oncological surgery in patients with metastatic cancer treated with angiogenesis inhibitors: Safe or not?

(1) Chua, Terence C a

a UNIVERSITY OF NEW SOUTH WALES (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; VASCULOTROPIN;

ARTERY THROMBOSIS; BLEEDING; CANCER CHEMOTHERAPY; CANCER SURGERY; COLORECTAL CANCER; CYTOREDUCTIVE SURGERY; DIGESTIVE SYSTEM PERFORATION; DRUG SAFETY; GLIOBLASTOMA; HUMAN; HYPERTENSION; LUNG NON SMALL CELL CANCER; METASTASIS; OVARY CANCER; POSTOPERATIVE COMPLICATION; PROTEINURIA; SHORT SURVEY; WOUND HEALING;

ANGIOGENESIS INHIBITORS; DIGESTIVE SYSTEM SURGICAL PROCEDURES; GASTROINTESTINAL NEOPLASMS; HUMANS; SAFETY; TREATMENT OUTCOME;

EID: 70350482135 PISSN: 14451433 EISSN: 14452197 Source Type: Journal
DOI: 10.1111/j.1445-2197.2009.05047.x Document Type: Short Survey

Times cited : (2)

References (7)

1
- 2542561964
- Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer
- Hurwitz H, Fehrenbacher L, Novotny W et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med. 2004 350 : 2335 2342.
- (2004) N. Engl. J. Med. , vol.350 , pp. 2335-2342
- Hurwitz, H.¹ Fehrenbacher, L.² Novotny, W.³

2
- 33845490014
- Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer
- DOI 10.1056/NEJMoa061884
- Sandler A, Gray R, Perry MC et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N. Engl. J. Med. 2006 355 : 2542 2550. (Pubitemid 44917502)
- (2006) New England Journal of Medicine , vol.355 , Issue.24 , pp. 2542-2550
- Sandler, A.¹ Gray, R.² Perry, M.C.³ Brahmer, J.⁴ Schiller, J.H.⁵ Dowlati, A.⁶ Lilenbaum, R.⁷ Johnson, D.H.⁸

3
- 33750344252
- Bevacizumab in the treatment of metastatic colorectal cancer: Safety profile and management of adverse events
- Hurwitz H, Saini S. Bevacizumab in the treatment of metastatic colorectal cancer: safety profile and management of adverse events. Semin. Oncol. 2006 33 : S26 34.
- (2006) Semin. Oncol. , vol.33 , pp. 26-34
- Hurwitz, H.¹ Saini, S.²

4
- 24344442899
- Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab
- Scappaticci FA, Fehrenbacher L, Cartwright T et al. Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab. J. Surg. Oncol. 2005 91 : 173 180.
- (2005) J. Surg. Oncol. , vol.91 , pp. 173-180
- Scappaticci, F.A.¹ Fehrenbacher, L.² Cartwright, T.³

5
- 33846603686
- Lack of evidence for increased operative morbidity after hepatectomy with perioperative use of bevacizumab: A matched case-control study
- D'Angelica M, Kornprat P, Gonen M et al. Lack of evidence for increased operative morbidity after hepatectomy with perioperative use of bevacizumab: a matched case-control study. Ann. Surg. Oncol. 2007 14 : 759 765.
- (2007) Ann. Surg. Oncol. , vol.14 , pp. 759-765
- D'Angelica, M.¹ Kornprat, P.² Gonen, M.³

6
- 44649192971
- Surgical morbidity associated with administration of targeted molecular therapies before cytoreductive nephrectomy or resection of locally recurrent renal cell carcinoma
- Margulis V, Matin SF, Tannir N et al. Surgical morbidity associated with administration of targeted molecular therapies before cytoreductive nephrectomy or resection of locally recurrent renal cell carcinoma. J. Urol. 2008 180 : 94 8.
- (2008) J. Urol. , vol.180 , pp. 94-98
- Margulis, V.¹ Matin, S.F.² Tannir, N.³

7
- 34249894171
- Gastrointestinal perforation due to bevacizumab in colorectal cancer
- Saif MW, Elfiky A, Salem RR. Gastrointestinal perforation due to bevacizumab in colorectal cancer. Ann. Surg. Oncol. 2007 14 : 1860 1869.
- (2007) Ann. Surg. Oncol. , vol.14 , pp. 1860-1869
- Saif, M.W.¹ Elfiky, A.² Salem, R.R.³

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.